Jupiter Neurosciences, Inc. (JUNS)
Nasdaq: JUNS · Pharmaceutical Preparations · Jupiter, FL · filing with the SEC since 2016
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Apr 1, 2026 | Mar 28, 2025 | · |
| Revenue | 21,796 | 0 | · |
| Cost of revenue | 4,231 | · | · |
| Gross profit | 17,565 | · | · |
| Research and development | 2,086,574 | 492,660 | 954,793 |
| Selling, general and administrative | 6,839,712 | · | · |
| General and administrative | 6,839,712 | 2,598,622 | 2,915,978 |
| Total operating expenses | 8,926,286 | 3,091,282 | 3,870,771 |
| Operating income | -8,908,721 | -3,091,282 | -3,870,771 |
| Interest expense | 66,020 | 248,366 | 218,705 |
| Interest and investment income | · | 5,557 | 482 |
| Total non-operating income (expense) | 263,824 | 651,657 | -912,918 |
| Net income | -8,644,897 | -2,439,625 | -4,783,689 |
| Earnings per share, basic | -0.25 | -0.08 | -0.18 |
| Earnings per share, diluted | -0.25 | -0.08 | -0.18 |
| Weighted average shares, basic | 34,628,588 | 28,783,045 | 26,405,109 |
| Weighted average shares, diluted | 34,628,588 | 28,783,045 | 26,405,109 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding